{
    "clinical_study": {
        "@rank": "148103", 
        "arm_group": [
            {
                "arm_group_label": "Cohort1", 
                "arm_group_type": "Experimental", 
                "description": "HM10660A SC once weekly"
            }, 
            {
                "arm_group_label": "Cohort2", 
                "arm_group_type": "Experimental", 
                "description": "HM10660A SC once every 2 weeks"
            }, 
            {
                "arm_group_label": "Cohort3", 
                "arm_group_type": "Experimental", 
                "description": "HM10660A SC once every 4 weeks"
            }, 
            {
                "arm_group_label": "Cohort4", 
                "arm_group_type": "Active Comparator", 
                "description": "180 mcg Pegasys SC once weekly"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and tolerability of multiple ascending\n      doses of HM10660A in subjects with chronic hepatitis C(HCV)."
        }, 
        "brief_title": "Safety,Tolerability and Pharmacokinetic Study of Recombinant Human Interferon Alfa 2B in Chronic Hepatitis C Patients (HM10660A)", 
        "condition": "Chronic Hepatitis C Virus Genotype I", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "-  To evaluate the repeat-dose pharmacokinetics (PK) of HM10660A when given by weekly,\n           biweekly, and monthly subcutaneous (SC) injection.\n\n        -  To evaluate the repeat-dose pharmacodynamics (PD) of HM10660A when given by weekly,\n           biweekly, and monthly SC injection.\n\n        -  To explore the antiviral activity of HM10660A at Week 4, Week 12, and Week 24."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female, aged 18 to 65 years old, inclusive\n\n          -  Willing and able to provide written informed consent.\n\n          -  Previously untreated HCV infection with HCV RNA > 75,000 IU/mL at screening.\n\n          -  HCV genotype 1a or 1b.\n\n          -  Body mass index (BMI) between 18 and 38 kg/m2.\n\n          -  Willing and able to comply with the protocol and available to complete the study\n             schedule of assessments.\n\n        Exclusion Criteria:\n\n          -  Pregnant women or women who may wish to become pregnant during the course of the\n             study.\n\n          -  Males and females of reproductive potential who are unwilling to use 2 forms of\n             effective birth control throughout the duration of study treatment and for at least 6\n             months after the last dose of RBV. One method should include a condom with spermicide\n             for males. Males must agree to refrain from sperm donation for at least 6 months\n             after the last dose of RBV.\n\n          -  Evidence of infection or co-infection with a non-genotype 1 HCV strain.\n\n          -  Co-infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV).\n\n          -  Lactating females"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "64", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02057887", 
            "org_study_id": "HM-IFN-201"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort1", 
                    "Cohort2", 
                    "Cohort3"
                ], 
                "intervention_name": "HM10660A", 
                "intervention_type": "Drug", 
                "other_name": "Laps-IFNa"
            }, 
            {
                "arm_group_label": "Cohort4", 
                "description": "180 mcg Pegasys SC once weekly", 
                "intervention_name": "Pegasys", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Peginterferon alfa-2a"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 6, 2014", 
        "location": {
            "contact": {
                "email": "clinical4@hanmi.co.kr", 
                "last_name": "Hanmi Clinical"
            }, 
            "facility": {
                "address": {
                    "city": "Estado de Mexico", 
                    "country": "Mexico"
                }, 
                "name": "Hanmi Clinical"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Mexico"
        }, 
        "number_of_arms": "4", 
        "overall_contact": {
            "email": "clinical4@hanmi.co.kr", 
            "last_name": "Hanmi Clinical"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Mexico: Federal Commission for Sanitary Risks Protection"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "HCV RNA Viral load", 
                "safety_issue": "No", 
                "time_frame": "Through study week 32"
            }, 
            {
                "description": "symptom-directed physical examination, Vital signs, Inspection of the Injection site, Complete Physical examination, 12-lead ECG, Hematology/coagulation", 
                "measure": "Safety/tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Through study week 32"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02057887"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Rapid virologic response (RVR)", 
                "safety_issue": "No", 
                "time_frame": "Study Week 4"
            }, 
            {
                "measure": "Early virologic response (EVR)", 
                "safety_issue": "No", 
                "time_frame": "Study week 12"
            }, 
            {
                "measure": "Sustained virologic response (SVR)", 
                "safety_issue": "No", 
                "time_frame": "Study week 24"
            }
        ], 
        "source": "Hanmi Pharmaceutical Company Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hanmi Pharmaceutical Company Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}